Roche Holding AG (ROG.VX)

ROG.VX on Virt-X Level 1

262.80CHF
4:40am EDT
Price Change (% chg)

CHF0.60 (+0.23%)
Prev Close
CHF262.20
Open
CHF262.20
Day's High
CHF263.20
Day's Low
CHF261.90
Volume
101,478
Avg. Vol
1,112,917
52-wk High
CHF274.80
52-wk Low
CHF226.30

ROG.VX

Chart for ROG.VX

About

Roche Holding AG is a Swiss pharmaceuticals and diagnostics holding company. It belongs to the Roche Group that operates through subsidiaries and associated companies around the world. It discovers, develops and provides diagnostic and therapeutic products and services from early detection and prevention of diseases to... (more)

Overall

Beta: 0.87
Market Cap (Mil.): CHF225,491.91
Shares Outstanding (Mil.): 862.56
Dividend: 7.80
Yield (%): 2.97

Financials

  ROG.VX Industry Sector
P/E (TTM): 20.27 35.07 35.49
EPS (TTM): 12.94 -- --
ROI: 26.20 18.94 18.21
ROE: 66.04 19.73 19.11
Search Stocks

French lawmakers back Roche cancer drug as cheap eye treatment

* EU shift to Avastin a threat to Novartis, Bayer profits

08 Jul 2014

Roche to buy U.S. biotech firm Seragon for up to $1.7 billion

ZURICH - Roche Holding AG ROG.VX said it would pay up to $1.725 billion to buy Seragon Pharmaceuticals, a privately-held U.S. biotech company that researches breast cancer treatments. | Video

02 Jul 2014

UPDATE 6-Roche to buy U.S. biotech firm Seragon for up to $1.7 bln

* Price $725 mln cash and up to $1 bln in milestone payments

02 Jul 2014

France to back Roche cancer drug as cheaper eye treatment

PARIS - The French government, looking to cut healthcare costs, plans to authorize the use of Roche cancer drug Avastin as an alternative eye disease treatment to the much pricier Lucentis, marketed by both Roche and Novartis.

02 Jul 2014

UPDATE 1-France to back Roche cancer drug as cheaper eye treatment

PARIS, July 2 - The French government, looking to cut healthcare costs, plans to authorise the use of Roche cancer drug Avastin as an alternative eye disease treatment to the much pricier Lucentis, marketed by both Roche and Novartis.

02 Jul 2014

France to back Roche cancer drug as cheaper eye treatment

PARIS, July 2 - The French government, looking to cut healthcare costs, plans to authorize the use of Roche cancer drug Avastin as an alternative eye disease treatment to the much pricier Lucentis, marketed by both Roche and Novartis.

02 Jul 2014

BUZZ -Curis Inc: Partner Roche seeks approval to start lung drug trial

** Says drug development partner Roche Holding AG filed for an U.S. regulatory approval to start mid-stage trial on their lung disease drug

23 Jun 2014

Roche to partner with Inception, Versant on MS research

ZURICH - Swiss drugmaker Roche said it will partner with Inception Sciences Inc. and Versant Ventures on a new company to develop therapies for patients with multiple sclerosis.

23 Jun 2014

Roche to partner with Inception, Versant on MS research

ZURICH, June 23 - Swiss drugmaker Roche said it will partner with Inception Sciences Inc. and Versant Ventures on a new company to develop therapies for patients with multiple sclerosis.

23 Jun 2014

UPDATE 1-Novartis says slimmer structure to boost profitability

* Shares rise 0.4 pct, outperform sector (Adds details, fresh CEO quote, shares)

18 Jun 2014

Earnings vs. Estimates

Search Stocks